You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Have you ever wondered how something became viral on social media? Or whether people in your state are ...

The S&P 500 recorded its ninth straight daily gain on Tuesday. The S&P 500's latest string of records has come with a catch: Fewer stocks are participating in the rally. That could leave the large-cap ...

The equity risk premium has effectively vanished. While it is a signal worth heeding, it is not cause for immediate alarm, particularly for portfolios that are genuinely diversified. In recent weeks ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Erik Steiger discusses the operational pain ...

Wall Street is chasing AI momentum and leaving much of the market in the dust, but the smaller stocks are keeping up. The Invesco S&P 500 Equal Weight ETF, which counts every S&P 500 stock as if they ...

Say goodbye to the Google search bar you’ve known for 25 years. The company is making it bigger and more interactive. The redesign is a response to AI, which has changed the way people search. Instead ...

Abstract: Breadth-first search (BFS) is a cornerstone in graph traversal, widely employed in areas such as social network analysis, routing algorithms, and biological network exploration. As the size ...

Search engines now rely on AI-driven systems that continuously evaluate authority, freshness, and first-party signals to decide which sources are trusted and used in answers. Search has not become ...

What’s unusual today is the degree of divergence between individual stocks and the cap-weighted index. The single most damaging decision most investors make during periods of falling stock market ...

(RTTNews) - Kymera Therapeutics, Inc. (KYMR) announced that the first patient has been dosed in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective degrader of STAT6, in ...

Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: ...

Netflix launched its first major foray into broadcast-style reality competition programming on Tuesday night. Star Search, a reboot of the 1980s series, is the streamer’s attempt to finally crack the ...